Your session is about to expire
← Back to Search
Inotuzumab + Blinatumomab for Acute Lymphoblastic Leukemia
Study Summary
This trial is testing inotuzumab ozogamicin and blinatumomab to see if they can help treat patients with CD22-positive B-lineage acute lymphoblastic leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What potential risks are associated with Inotuzumab Ozogamicin treatment?
"With the limited clinical data available, inotuzumab ozogamicin was assessed a safety score of 2 out of 3. Since this is only a phase two trial, there are no records yet indicating its efficacy."
Are there any available opportunities for people to participate in this experiment?
"According to the records on clinicaltrials.gov, this research effort is in need of participants. It was initially announced November 16th 2018 and had a recent update November 30th 2022."
How many distinct sites are involved in the execution of this experiment?
"This study is currently enrolling patients from 81 different sites, ranging from Clackamas to Rice Lake and Madison. To lessen the burden of travel costs, it may be prudent to select a site nearby your own location before signing up for this trial."
Has Inotuzumab Ozogamicin been subject to any prior scientific testing?
"Inotuzumab Ozogamicin was initially trialled in 2011 at M D Anderson Cancer Center and has since been studied 38 times. Currently, 62 trials of this medication are being conducted across the world with a significant number hosted by Clackamas, Oregon."
What indications are generally associated with Inotuzumab Ozogamicin?
"Inotuzumab Ozogamicin is employed to treat cases of refractory b-cell precursor acute lymphoblastic leukemia and relapsed b cell precursor acute lymphoblastic leukaemia. It may also be utilized in the context of kidney or heart transplantation."
Share this study with friends
Copy Link
Messenger